Bridgebio Pharma vs Ionis Pharmaceuticals
Ionis Pharmaceuticals is the larger business, with $944m of revenue in fiscal 2025 against $502m for Bridgebio Pharma (1.9 times as much). Bridgebio Pharma grew faster (126.3% against 33.8%). Ionis Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -40.4% against -144.4%.
| Latest fiscal year | Bridgebio PharmaBBIO, 2025 | Ionis PharmaceuticalsIONS, 2025 |
|---|---|---|
| Revenue | $502m | $944m |
| Revenue growth | 126.3% | 33.8% |
| Net income | −$725m | −$381m |
| Operating margin | -104.2% | -40.4% |
| Net margin | -144.4% | -40.4% |
| Return on equity | — | -70.8% |
| Free cash flow | −$447m | −$320m |
| Cash | $570m | $372m |
| Total debt | $2.01bn | $1.81bn |
| Debt to equity | — | 370.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $48.3m | — |
| Employees | 834 | 1,402 |
| Market value | $14.64bn | $6.75bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 143 sales | 2 buys, 116 sales |